Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
about
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinDual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.Natural product and natural product derived drugs in clinical trials.Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsPM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
P2860
Q34898364-90BF803F-7524-40CF-97F1-856E30B62DB1Q35960779-BC6F415B-3735-405E-B910-6E34D5FF7042Q36432104-6D822946-EE7F-4B3C-A6F4-E2E55817788EQ37295535-9AA1198C-3F9B-4915-BD44-18791C8F5ADEQ37545395-F602FED0-F81D-4781-ABF4-EE3F3B4C5633Q37566220-E1738735-4B9D-48FB-B582-677668EA07ADQ37628646-42D07BC5-6BF9-452E-BAE8-FBAFBA9A8D4FQ38206366-D1C0F17F-9904-47FA-9A70-25DE489A6AA1Q38247457-25E25C93-D496-47FD-8FD8-E041DFD07FB8Q38748263-E380CF14-14F1-41C3-BB2A-97D17E1432BAQ40105033-90A692C0-5735-42D0-8A12-E14AB641A198Q41524895-1B4196CF-5DAC-4B17-AC4F-278773FFF9EAQ50213474-A087C317-6144-480B-9D8C-5B67085B6938Q58702635-2C1B74F0-B00C-4057-8267-9B5AAC3DB587
P2860
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@ast
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@en
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@nl
type
label
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@ast
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@en
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@nl
prefLabel
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@ast
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@en
Comparison of in vitro and in ...... 1183) and Zalypsis® (PM00104).
@nl
P2093
P2860
P50
P356
P1476
Comparison of in vitro and in ...... 01183) and Zalypsis® (PM00104)
@en
P2093
Carlos M Galmarini
Carmen Cuevas
Eugenio Erba
Luca Porcu
Luis F García-Fernández
Michela Romano
Monique Zangarini
Paola Allavena
P2860
P304
P356
10.1002/IJC.28213
P577
2013-05-25T00:00:00Z